Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00200395
Status:
COMPLETED
Last Update Posted:
2019-12-30
First Post:
2005-09-13
Brief Title:
OSI-774 Erlotinib Tarceva in Elderly Patients
Sponsor:
Montefiore Medical Center
Organization:
Montefiore Medical Center
Study Overview
Official Title:
Phase II Study of OSI-774 Erlotinib Tarceva in Elderly Patients With Advanced Stage or Inoperable Non Small Cell Lung Cancer NSCLC
Status:
COMPLETED
Status Verified Date:
2019-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research study is to determine if OSI-774 Tarceva is effective in the treatment of non-small cell lung cancer and to further study its side effects The investigators would also like to estimate disease-related symptom improvement rates using a questionnaire
Detailed Description:
In recent years it has been shown that the degree of improvement achievable with chemotherapy has plateaued with the use of chemotherapy doublets The presence of co-morbid conditions and poor performance status may preclude the use of chemotherapy in many elderly patients which even in the medically fit has modest benefits The advent of targeted cancer therapy with the discovery of tyrosine kinases as mediators of tumor growth with its limited toxicity profile offers a promising approach to the treatment of NSCLC in particular to the elderly subset of patients The encouraging results from the other trials provide a strong rationale to evaluate an oral EGFR-tyrosine kinase inhibitor OSI-774 in patients with advanced and inoperable NSCLC over the age of 70 In vitro and clinical data suggest a dose- dependent response with Tarceva Genentech data on file
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None